Planning mantle radiation therapy in patients with Hodgkin disease: role of gallium-67 scintigraphy

Jochelson,; Herman, TS; Stomper, Paul C.; Mauch, P; Kaplan, W. D.

doi:10.2214/ajr.151.6.1229

Cited by 25 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The major problem in the post‐treatment evaluation of patients with HD is the presence of a residual mass, which is found in up to 88% of patients with mediastinal HD (Jochelson et al , 1988). The management of these residual masses represents a continuing dilemma for the clinician.…”

Section: Discussionmentioning

confidence: 99%

Can positron emission tomography with [¹⁸F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

et al. 2001

View full text Add to dashboard Cite

To assess the ability of restaging positron emission tomography (PET) scanning to predict clinical outcome after first‐line treatment in patients with Hodgkin's disease, we included 60 patients with histologically proven HD, who underwent whole‐body [18F]‐fluorodeoxygenase ([18F]‐FDG)‐PET studies after first‐line treatment and with a follow‐up of at least 1 year. Persistence or absence of residual disease on PET was related to progression‐free survival (PFS) using Kaplan–Meier survival analysis. After treatment, 55 patients showed a normal [18F]‐FDG‐PET scan; 50 of 55 remained in complete remission (CR), with a median follow‐up of 955 d. Only five patients relapsed (median PFS, 296 d). During follow‐up in all five patients, [18F]‐FDG‐PET was the first tool that became positive for relapse. Persistent abnormal [18F]‐FDG uptake was seen in only five patients; all of them relapsed (median PFS, 296 d). In four of five patients, only PET predicted persistent disease. All relapses were proven histologically. Two‐year actuarial PFS rate for negative patients was 91% compared with 0% for positive patients. We concluded that [18F]‐FDG‐PET has an important prognostic role in the post‐treatment evaluation of HD patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Can positron emission tomography with [¹⁸F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

et al. 2001

View full text Add to dashboard Cite

show abstract

“…Occasionally, 67 Ga scintigraphy upgrades disease to stage IV by demonstrating bone lesions or other unsuspected extranodal sites [13,21,22]. For conventional X-ray methods and MRI whole body imaging is no option.…”

Section: Ga Scintigraphy Prior To Treatmentmentioning

confidence: 99%

Role of 67 Ga scintigraphy in localization of lymphoma

Amsterdam

Kluin-Nelemans

Eck-Smit

et al. 1996

Annals of Hematology

View full text Add to dashboard Cite

This review deals with the applications of 67Gallium (Ga) scintigraphy for the initial staging and follow-up during and after treatment of patients with Hodgkin's or non-Hodgkin's lymphoma (NHL). During the last decade, the technique of visualization has been largely improved by using higher doses and additional tomography. Here, the indications for 67Ga scintigraphy in comparison with CT and MRI are discussed. The conditions resulting in false positive and false negative results have been outlined. 67Ga may detect unusual involved sites during staging procedures. However, the major contribution to the management of Hodgkin's disease and NHL is the evaluation of residual masses, because 67Ga uptake reflects the metabolic activity of the tumor. The review ends with an additional short overview of other radionuclide imaging methods useful for malignant lymphoma.

show abstract

“…Gallium scanning also has been utilized in the evaluation of disease stage [18,19]. This radionuclide study has a low sensitivity when used in untreated patients (64%), but a high specificity (98%).…”

Section: Initial Evaluation Of Patients With Hodgkin's Diseasementioning

confidence: 99%

“…Thus, a positive study is highly predictive of active disease, but a negative study is not definitive. Both chest CT and gallium scanning have been employed to assess mediastinal disease, at initial presentation and in follow-up [18][19][20][21][22]. Radiographic abnormalities of the mediastinum may persist in greater than two-thirds of patients post-therapy, especially those with initial bulky mediastinal disease.…”

Section: Initial Evaluation Of Patients With Hodgkin's Diseasementioning

confidence: 99%

Staging Laparotomy in the Management of Hodgkin's Disease: Is it Still Necessary?

Multani

Grossbard

1996

The Oncologist

View full text Add to dashboard Cite

Approximately 3,500 cases of stage I and II Hodgkin's disease are diagnosed each year in the United States. Traditionally, those patients who are considered candidates for primary radiation therapy undergo staging laparotomy (pathologic staging) to rule out definitively the presence of occult subdiaphragmatic disease. An appreciation of the risks of laparotomy and a recognition of the effectiveness of salvage chemotherapy in patients who fail primary radiation therapy have permitted the increased use of clinical staging as the basis for treatment of these patients. This article summarizes the literature regarding the need for staging laparotomy in early stage Hodgkin's disease and suggests alternative approaches to the management of these patients based on clinical criteria and prognostic factors.

show abstract

Planning mantle radiation therapy in patients with Hodgkin disease: role of gallium-67 scintigraphy

Cited by 25 publications

References 6 publications

Can positron emission tomography with [¹⁸F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

Can positron emission tomography with [¹⁸F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

Role of 67 Ga scintigraphy in localization of lymphoma

Staging Laparotomy in the Management of Hodgkin's Disease: Is it Still Necessary?

Contact Info

Product

Resources

About

Planning mantle radiation therapy in patients with Hodgkin disease: role of gallium-67 scintigraphy

Cited by 25 publications

References 6 publications

Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

Role of 67 Ga scintigraphy in localization of lymphoma

Staging Laparotomy in the Management of Hodgkin's Disease: Is it Still Necessary?

Contact Info

Product

Resources

About

Can positron emission tomography with [¹⁸F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

Can positron emission tomography with [¹⁸F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?